k 2023

Synthesis and evaluation of biological activity of newly designed hydroxamates as potential HDAC inhibitors

ONUŠČÁKOVÁ, Magdaléna, Hana PÍŽOVÁ, Tereza KAUEROVÁ, Peter KOLLÁR, Pavel BOBÁĽ et. al.

Basic information

Original name

Synthesis and evaluation of biological activity of newly designed hydroxamates as potential HDAC inhibitors

Name in Czech

Syntéza a hodnocení biologické aktivity nově navržených hydroxamátů jako potenciálních inhibitorů HDAC

Authors

ONUŠČÁKOVÁ, Magdaléna (703 Slovakia, belonging to the institution), Hana PÍŽOVÁ (203 Czech Republic, belonging to the institution), Tereza KAUEROVÁ (203 Czech Republic, belonging to the institution), Peter KOLLÁR (203 Czech Republic, belonging to the institution) and Pavel BOBÁĽ (703 Slovakia, belonging to the institution)

Edition

57th Conference: Advances in Organic, Bioorganic and Pharmaceutical Chemistry – Liblice. 2023

Other information

Language

English

Type of outcome

Prezentace na konferencích

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14160/23:00133253

Organization unit

Faculty of Pharmacy

Keywords in English

HDAC inhibitors; Hydroxamic acids; Antineoplastic activity

Tags

Změněno: 5/4/2024 07:31, Mgr. Daniela Černá

Abstract

V originále

Histone deacetylases (HDACs) are metalloenzymes involved in the regulation of fundamental cellular processes, such as cell cycle progression, differentiation, and tumorigenesis. The abnormal function of HDACs can induce severe human diseases, including cancer, pulmonary disease, and neurodegenerative disorders.1 Histone deacetylase inhibitors (HDACi) represent a relatively new generation of drugs with the ability to affect the expression of specific genes, which can repair controlled proliferation or damage apoptotic processes in tumor cells

Links

EF19_073/0016943, research and development project
Name: Interní grantová agentura Masarykovy univerzity
MUNI/IGA/1339/2021, interní kód MU
Name: Design, synthesis and evaluation of potential metalloenzymes inhibitors (Acronym: DSEPMI)
Investor: Masaryk University